Article: Endovasc Announces Plans to Bypass Phase II Liprostin Clinical Trials and Proceed to Phase III.

Business Editors/Health & Medical Writers

BIOWIRE2K

MONTGOMERY, Texas--(BW HealthWire)--May 7, 2001

Endovasc Ltd. Inc. (OTCBB:ENDV) today announced plans to move directly into Phase III human trials with Critical Limb Ischemic patients.

Having demonstrated very successful results from the recently concluded animal studies as well as a significant safety profile in Phase I human trials in healthy volunteers, Endovasc Ltd. Inc. has determined it will proceed with Phase III, i.e., the last phase of IND clinical development, as recommended by the Food and Drug Administration at their October 1999 Pre-Investigational New Drug Application ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!